The U.S. Food and Drug Administration (FDA) has approved carbidopa-levodopa-entacapone (Stalevo®) to treat Parkinson's disease in the following situations:
- As a substitution for carbidopa-levodopa (Sinemet®) plus entacapone (Comtan®) in people already taking these medications
- As a replacement for carbidopa-levodopa in people experiencing "wearing-off" symptoms who take 600 mg of levodopa per day or less and who are not experiencing dyskinesia (a movement disorder that is a side effect of carbidopa-levodopa).
Prior to prescribing carbidopa-levodopa-entacapone, your healthcare provider needs information on your complete medical history and any other drugs you are taking. This will help ensure a safe, effective treatment process.
(Click Carbidopa-Levodopa-Entacapone for more information, including how this medication works, side effects to be aware of, and general dosing guidelines.)